London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’

Buobe IA context · why it matters

Poolbeg Pharma is testing an oral drug at six NHS hospitals — This could provide a safer treatment option for blood cancer patients by preventing cytokine release syndrome.
The company is also developing a GLP-1 weight loss pill — This suggests Poolbeg Pharma has multiple product lines, potentially diversifying its revenue streams. Fique de olho
The success of the trial may lead to broader adoption of immunotherapy treatments.

Published by

on •1 min read

London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’

Poolbeg Pharma to test the treatment in NHS hospitals and says it is also developing a GLP-1 weight loss pillA London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect.

Pharmaceuticals industry Cancer Immunology London Business Health UK news Johnson Medical research Drugs Biotechnology industry Biochemistry and molecular biology Chemistry Science Society Biology

Learn more